Patents by Inventor Stuart B. Rosenblum

Stuart B. Rosenblum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7300941
    Abstract: Disclosed are novel compounds of the formula Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H1 receptor antagonist.
    Type: Grant
    Filed: October 31, 2003
    Date of Patent: November 27, 2007
    Assignee: Schering Corporation
    Inventors: Robert G. Aslanian, Neng-Yang Shih, Pauline C. Ting, Michael Y. Berlin, Stuart B. Rosenblum, Kevin D. McCormick, Wing C. Tom, Christopher W. Boyce, Pietro Mangiaracina, Mwangi W. Mutahi, John J. Piwinski
  • Patent number: 7238688
    Abstract: Disclosed are novel compounds of the formula Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H1 receptor antagonist.
    Type: Grant
    Filed: October 27, 2004
    Date of Patent: July 3, 2007
    Assignee: Schering Corporation
    Inventors: Stuart B. Rosenblum, Qingbei Zeng, Mwangi Wa Mutahi, Robert G. Aslanian, Pauline C. Ting, Neng-Yang Shih, Daniel M. Solomon, Jianhua Cao, Henry A. Vaccaro, Kevin D. McCormick, John J. Baldwin, Ge Li
  • Patent number: 7220735
    Abstract: Disclosed are novel compounds of the formula wherein R1 is benzimidazolone derivative, M1 and M2 are optionally substituted carbon or nitrogen, R2 includes optionally substituted aryl or heteroaryl, and the remaining variables are as defined in the specification, and the remaining variables are as defined in the specification; also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating various diseases or conditions, such as allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I, as well as methods of treating said diseases or conditions using the compounds of formula I in combination with an H1 receptor antagonist.
    Type: Grant
    Filed: April 16, 2003
    Date of Patent: May 22, 2007
    Assignee: Schering Corporation
    Inventors: Pauline C. Ting, Robert G. Aslanian, Michael Y. Berlin, Christopher W. Boyce, Jianhua Cao, Pietro Mangiaracina, Kevin D. McCormick, Mwangi W. Mutahi, Stuart B. Rosenblum, Neng-Yang Shih, Daniel M. Solomon, Wing C. Tom, Qingbei Zeng
  • Patent number: 7105505
    Abstract: Disclosed are novel compounds of the formula wherein R1 is optionally substituted benzimidazolyl or a derivative thereof; R2 is optionally substituted aryl or heteroaryl; M1 and M2 are C(R3) or N; and the remaining variables are as defined in the specification; also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating various diseases or conditions, such as allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I, as well as methods of treating said diseases or conditions using the compounds of formula I in combination with an H1 receptor antagonist.
    Type: Grant
    Filed: April 16, 2003
    Date of Patent: September 12, 2006
    Assignee: Schering Corporation
    Inventors: Qingbei Zeng, Robert G. Aslanian, Michael Y. Berlin, Christopher W. Boyce, Jianhua Cao, Joseph A. Kozlowski, Pietro Mangiaracina, Kevin D. McCormick, Mwangi W. Mutahi, Stuart B. Rosenblum, Neng-Yang Shih, Daniel M. Solomon, Wing C. Tom
  • Patent number: 6951871
    Abstract: Disclosed are novel compounds of the formula wherein M1 is CH or N and M2 is C(R3) or N; R1 is optionally substituted indolyl or an aza derivative thereof; R2 is optionally substituted aryl or heteroaryl; and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I in combination with a H1 receptor antagonist.
    Type: Grant
    Filed: June 20, 2003
    Date of Patent: October 4, 2005
    Assignee: Schering Corporation
    Inventors: Robert G. Aslanian, Michael Y. Berlin, Pietro Mangiaracina, Kevin D. McCormick, Mwangi W. Mutahi, Stuart B. Rosenblum
  • Patent number: 6849621
    Abstract: Disclosed are novel compounds of the formula Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H. receptor antagonist.
    Type: Grant
    Filed: March 11, 2002
    Date of Patent: February 1, 2005
    Assignees: Schering Corporation, Pharmacopeia Drug Discovery, Inc.
    Inventors: Stuart B. Rosenblum, Qingbei Zeng, Mwangi Wa Mutahi, Robert G. Aslanian, Pauline C. Ting, Neng-Yang Shih, Daniel M. Solomon, Jianhua Cao, Henry A. Vaccaro, Kevin D. McCormick, John J. Baldwin, Ge Li
  • Patent number: 6762186
    Abstract: The present invention discloses novel substituted imidazole compounds which have H3 receptor antagonist or dual histamine-H1 and H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazoles as well as methods of using them to treat allergy, nasal congestion, inflammatory and CNS-related diseases and others.
    Type: Grant
    Filed: September 18, 2001
    Date of Patent: July 13, 2004
    Assignee: Schering Corporation
    Inventors: Neng-Yang Shih, Robert G. Aslanian, Daniel M. Solomon, Stuart B. Rosenblum, Mwangi Wa Mutahi, Tom G. Wing, Kevin D. McCormick, John J. Piwinski, Ronald Wolin
  • Publication number: 20040097483
    Abstract: Disclosed are novel compounds of the formula 1
    Type: Application
    Filed: April 16, 2003
    Publication date: May 20, 2004
    Inventors: Qingbei Zeng, Robert G. Aslanian, Michael Y. Berlin, Christopher W. Boyce, Jianhua Cao, Joseph A. Kozlowski, Pietro Mangiaracina, Kevin D. McCormick, Mwangi W. Mutahi, Stuart B. Rosenblum, Neng-Yang Shih, Daniel M. Solomon, Wing C. Tom
  • Publication number: 20040097513
    Abstract: Disclosed are novel compounds of the formula 1
    Type: Application
    Filed: October 31, 2003
    Publication date: May 20, 2004
    Inventors: Robert G. Aslanian, Neng-Yang Shih, Pauline C. Ting, Michael Y. Berlin, Stuart B. Rosenblum, Kevin D. McCormick, Wing C. Tom, Christopher W. Boyce, Pietro Mangiaracina, Mwangi W. Mutahi, John J. Piwinski
  • Patent number: 6720328
    Abstract: Disclosed are novel compounds of the formula In Formula I, M1 is carbon, M2, M3 and M4 are carbon or nitrogen and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H1 receptor antagonist.
    Type: Grant
    Filed: October 15, 2001
    Date of Patent: April 13, 2004
    Assignee: Schering Corporation
    Inventors: Robert G. Aslanian, Neng-Yang Shih, Pauline C. Ting, Michael Y. Berlin, Stuart B. Rosenblum, Kevin D. McCormick, Wing C. Tom, Christopher W. Boyce, Pietro Mangiaracina, Mwangi W. Mutahi, John J. Piwinski
  • Publication number: 20040048843
    Abstract: Disclosed are novel compounds of the formula 1
    Type: Application
    Filed: April 16, 2003
    Publication date: March 11, 2004
    Applicant: Schering Corporation
    Inventors: Pauline C. Ting, Robert G. Aslanian, Michael Y. Berlin, Christopher W. Boyce, Jianhua Cao, Pietro Mangiaracina, Kevin D. McCormick, Mwangi W. Mutahi, Stuart B. Rosenblum, Neng-Yang Shih, Daniel M. Solomon, Wing C. Tom, Qingbei Zeng
  • Publication number: 20040019099
    Abstract: Disclosed are novel compounds of the formula 1
    Type: Application
    Filed: June 20, 2003
    Publication date: January 29, 2004
    Applicant: Schering Corporation
    Inventors: Robert G. Aslanian, Michael Y. Berlin, Pietro Mangiaracina, Kevin D. McCormick, Mwangi W. Mutahi, Stuart B. Rosenblum
  • Publication number: 20030109564
    Abstract: Disclosed are novel compounds of the formula 1
    Type: Application
    Filed: March 11, 2002
    Publication date: June 12, 2003
    Applicant: Schering Corporation
    Inventors: Stuart B. Rosenblum, Qingbei Zeng, Mwangi Wa Mutahi, Robert G. Aslanian, Pauline C. Ting, Neng-Yang Shih, Daniel M. Solomon, Jianhua Cao, Henry A. Vaccaro, Kevin D. McCormick, John J. Baldwin, Ge Li
  • Publication number: 20030045519
    Abstract: Disclosed are novel compounds of the formula 1
    Type: Application
    Filed: October 15, 2001
    Publication date: March 6, 2003
    Inventors: Robert G. Aslanian, Neng-Yang Shih, Pauline C. Ting, Michael Y. Berlin, Stuart B. Rosenblum, Kevin D. McCormick, Wing C. Tom, Christopher W. Boyce, Pietro Mangiaracina, Mwangi W. Mutahi, John J. Piwinski
  • Patent number: 6440989
    Abstract: Novel phenyl-substituted tricyclic compounds and pharmaceutical compositions are disclosed which are inhibitors of the enzyme, farnesyl protein transferase. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering the novel halo-N-substituted urea compound to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammals such as a human.
    Type: Grant
    Filed: February 13, 2001
    Date of Patent: August 27, 2002
    Assignee: Schering Corporation
    Inventors: Adriano Afonso, Joseph M. Kelly, Jay Weinstein, Ronald L. Wolin, Stuart B. Rosenblum
  • Publication number: 20020103235
    Abstract: The present invention discloses novel substituted imidazole compounds which have either or dual histamine-H1 and H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazoles as well as methods of using them to treat allergy, inflammatory and CNS-related diseases and others.
    Type: Application
    Filed: September 18, 2001
    Publication date: August 1, 2002
    Inventors: Robert G. Aslanian, Stuart B. Rosenblum, Mwangi Wa Mutahi, Neng-Yang Shih, John J. Piwinski
  • Publication number: 20020082278
    Abstract: The present invention discloses novel substituted imidazole compounds which have H3 receptor antagonist or dual histamine-H1 and H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazoles as well as methods of using them to treat allergy, nasal congestion, inflammatory and CNS-related diseases and others.
    Type: Application
    Filed: September 18, 2001
    Publication date: June 27, 2002
    Inventors: Neng-Yang Shih, Robert G. Aslanian, Daniel M. Solomon, Stuart B. Rosenblum, Mwangi Wa Mutahi, Wing C. Tom, Kevin D. Mc Cormick, John J. Piwinski, Ronald Wolin
  • Publication number: 20010016585
    Abstract: Novel phenyl-substituted tricyclic compounds and pharmaceutical compositions are disclosed which are inhibitors of the enzyme, farnesyl protein transferase. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering the novel halo-N-substituted urea compound to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammals such as a human.
    Type: Application
    Filed: February 13, 2001
    Publication date: August 23, 2001
    Inventors: Adriano Afonso, Joseph M. Kelly, Jay Weinstein, Ronald L. Wolin, Stuart B. Rosenblum
  • Patent number: 6218401
    Abstract: Novel phenyl-substituted tricyclic compounds and pharmaceutical compositions are disclosed which are inhibitors of the enzyme, farnesyl protein transferase. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering the novel halo-N-substituted urea compound to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammals such as a human.
    Type: Grant
    Filed: August 13, 1999
    Date of Patent: April 17, 2001
    Assignee: Schering Corporation
    Inventors: Adriano Afonso, Joseph M. Kelly, Jay Weinstein, Ronald L. Wolin, Stuart B. Rosenblum
  • Patent number: RE37721
    Abstract: Hydroxy-substituted azetidinone hypocholesterolemic agents of the formula or a pharmaceutically acceptable salt thereof, wherein: Ar1 and Ar2 are aryl or R4-substituted aryl; Ar3 is aryl or R5-substituted aryl; X, Y and Z are —CH2—, —CH(lower alkyl)— or —C(dilower alkyl)—; R and R2 are —OR6, —O(CO)R6, —O(CO)OR9 or —O(CO)NR6R7; R1 and R3 are H or lower alkyl; q is 0 or 1; r is 0 or 1; m, n and p are 0-4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1-6; and provided that when p is O and r is 1, the sum of m, q and n is 1-5; R4 is selected from lower alkyl, R5, —CF3, —CN, —NO2 and halogen R5 is selected from —OR6, —O(CO)R6, —O(CO)OR9, —O(CH2)1-5OR6, —O(CO)NR6R7, —NR6R7, —NR6(CO)R7, —NR6(CO)OR9, —NR6(CO)NR7R8, —NR6SO2R9, —COOR6, —CONR6R7, —COR6, —SO2NR6R7, S(O)0-2R9, —O(CH2)1-10—COOR
    Type: Grant
    Filed: June 15, 2000
    Date of Patent: May 28, 2002
    Assignee: Schering Corporation
    Inventors: Stuart B. Rosenblum, Sundeep Dugar, Duane A. Burnett, John W. Clader, Brian A. McKittrick